menu
    • menu

    Company profile for Dianthus Therapeutics

    NEW Drugs in Dev: 2
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dianthus Therapeutics is advancing next generation complement therapeutics to deliver transformative medicines for patients with rare diseases. Our mission is to develop best-in-class, potent and selective antibodies of validated and emerging complement targets to transform the lives of people living with autoimmune diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dianthus TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Waltham, Massachusetts
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://dianthustx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dianthus-therapeutics-inc/about/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/dianthustx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dianthus Therapeutics to Participate in Two Investor Conferences
    Dianthus Therapeutics to Participate in Two Investor Conferences

    26 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/26/3301437/0/en/dianthus-therapeutics-to-participate-in-two-investor-conferences.html

    GLOBENEWSWIRE
    26 May 2026
    Share Share
    Dianthus Therapeutics Reports Q1 2026 Results, Key Wins
    Dianthus Therapeutics Reports Q1 2026 Results, Key Wins

    05 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7271213

    FIRSTWORD PHARMA
    05 May 2026
    Share Share
    Dianthus Issues Nasdaq-Compliant Inducement Grants
    Dianthus Issues Nasdaq-Compliant Inducement Grants

    01 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/01/3286227/0/en/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

    GLOBENEWSWIRE
    01 May 2026
    Share Share
    Dianthus Therapeutics Reveals Inducement Grants Per Nasdaq LR
    Dianthus Therapeutics Reveals Inducement Grants Per Nasdaq LR

    06 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/06/3268702/0/en/Dianthus-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    06 Apr 2026
    Share Share
    Dianthus Therapeutics Closes $719M Upsized Offering
    Dianthus Therapeutics Closes $719M Upsized Offering

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3255079/0/en/Dianthus-Therapeutics-Inc-Announces-Closing-of-its-Upsized-719-Million-Underwritten-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Dianthus Early GO In Ph3 Claseprubart CIDP Trial
    Dianthus Early GO In Ph3 Claseprubart CIDP Trial

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251679/0/en/Dianthus-Therapeutics-Announces-Early-GO-Decision-Following-Interim-Responder-Analysis-in-Phase-3-CAPTIVATE-Trial-of-Claseprubart-in-Chronic-Inflammatory-Demyelinating-Polyneuropat.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search